MTOR and small cell lung carcinoma: In small-cell lung cancer (SCLC) models, the combination of PI3K/mTOR inhibitors BEZ235 and GSK2126458 with radiotherapy significantly reduced the survival rates of SCLC cells, increased apoptosis rates to 24–32%, and markedly suppressed clonogenic capacity.